Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
Por:
Jacome, Rodrigo, Alberto Campillo-Balderas, Jose, PONCE DE LEON, SAMUEL, Becerra, Arturo, Lazcano, Antonio
Publicada:
9 jun 2020
Categoría:
Multidisciplinary
Resumen:
As of today, there is no antiviral for the treatment of the SARS-CoV-2
infection, and the development of a vaccine might take several months or
even years. The structural superposition of the hepatitis C virus
polymerase bound to sofosbuvir, a nucleoside analog antiviral approved
for hepatitis C virus infections, with the SARS-CoV polymerase shows
that the residues that bind to the drug are present in the latter.
Moreover, a multiple alignment of several SARS-CoV-2, SARS and
MERS-related coronaviruses polymerases shows that these residues are
conserved in all these viruses, opening the possibility to use
sofosbuvir against these highly infectious pathogens.
Filiaciones:
Jacome, Rodrigo:
Univ Nacl Autonoma Mexico, Fac Ciencias, Mexico City, DF, Mexico
Alberto Campillo-Balderas, Jose:
Univ Nacl Autonoma Mexico, Fac Ciencias, Mexico City, DF, Mexico
PONCE DE LEON, SAMUEL:
Univ Nacl Autonoma Mexico, Programa Univ Invest Salud, Mexico City, DF, Mexico
Becerra, Arturo:
Univ Nacl Autonoma Mexico, Fac Ciencias, Mexico City, DF, Mexico
Lazcano, Antonio:
Univ Nacl Autonoma Mexico, Fac Ciencias, Mexico City, DF, Mexico
Colegio Nacl, Mexico City, DF, Mexico
|